Business Context and Reporting Period
This Form 8-K is a current report filed by Intrexon Corporation (not Precigen, Inc.) on April 1, 2015. The filing addresses Item 8.01 (Other Events) regarding the resale of shares issued in connection with specific licensing and securities agreements.
Key Transaction Details
- Event: Filing of a prospectus supplement to a Form S-3ASR registration statement (File No. 333-198598).
- Purpose: To cover the resale of Intrexon common stock issued to ZIOPHARM Oncology, Inc. and The University of Texas System Board of Regents (on behalf of MD Anderson Cancer Center).
- Underlying Agreements:
- License agreement dated January 13, 2015.
- Letter agreement dated January 9, 2015.
- Related securities issuance agreements dated January 13, 2015.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding securities resale and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial performance or operational status are reported in this filing. The document solely reports the administrative step of filing a prospectus supplement to facilitate the resale of previously issued shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It does not disclose specific risks or contingencies beyond the standard legal opinion regarding the resale of shares.
Investor Verification Checklist
- Verify the exact number of shares issued to ZIOPHARM and MD Anderson in the January 2015 agreements.
- Review the full text of the license agreement and letter agreement to understand the commercial terms and royalty obligations.
- Confirm the status of the Form S-3ASR registration statement (File No. 333-198598) and any subsequent resale activity.
- Check for any subsequent filings regarding the financial impact of the ZIOPHARM/MD Anderson collaboration.